BACKGROUND: The expression of c-Met is substantially elevated in most malignant human cancers. We therefore searched for c-Met expression and compared the expression level among malignant skin cancers. OBJECTIVE: The aim of this study was to determine the c-Met expression pattern and the protein expression level in selected malignant cutaneous tumors. METHODS: G361 cells (malignant melanoma cell line) and A431 cells (squamous cell carcinoma cell line) were cultured and analyzed, using immunoprecipitation and Western blot analysis, for expression of c-Met. Additionally, 16 separate specimens of malignant melanomas (MMs), 16 squamous cell carcinomas (SCCs), 16 basal cell carcinomas (BCCs) and 16 normal tissues were analyzed for the expression of c-Met using immunohistochemical studies. RESULTS: Based on cultured cell immunoprecipitation and Western blot analysis, both A431 cells and G361 cells expressed c-Met, however, c-Met was expressed substantially more in G361 cells. Immunohistochemical examination of c-Met showed that it was over-expressed in all malignant skin cancers. In addition, c-Met expression was more increased in MM compared to other cancers. CONCLUSION: In our study, c-Met is involved in malignant skin cancer development and the level of its expression is thought to be related to the degree of malignancy in melanoma cancers.
BACKGROUND: The expression of c-Met is substantially elevated in most malignant humancancers. We therefore searched for c-Met expression and compared the expression level among malignant skin cancers. OBJECTIVE: The aim of this study was to determine the c-Met expression pattern and the protein expression level in selected malignant cutaneous tumors. METHODS: G361 cells (malignant melanoma cell line) and A431 cells (squamous cell carcinoma cell line) were cultured and analyzed, using immunoprecipitation and Western blot analysis, for expression of c-Met. Additionally, 16 separate specimens of malignant melanomas (MMs), 16 squamous cell carcinomas (SCCs), 16 basal cell carcinomas (BCCs) and 16 normal tissues were analyzed for the expression of c-Met using immunohistochemical studies. RESULTS: Based on cultured cell immunoprecipitation and Western blot analysis, both A431 cells and G361 cells expressed c-Met, however, c-Met was expressed substantially more in G361 cells. Immunohistochemical examination of c-Met showed that it was over-expressed in all malignant skin cancers. In addition, c-Met expression was more increased in MM compared to other cancers. CONCLUSION: In our study, c-Met is involved in malignant skin cancer development and the level of its expression is thought to be related to the degree of malignancy in melanoma cancers.
Authors: L W Chung; W Li; M E Gleave; J T Hsieh; H C Wu; R A Sikes; H E Zhau; M G Bandyk; C J Logothetis; J S Rubin Journal: J Cell Biochem Suppl Date: 1992
Authors: Cuixia Cai; Rong Shi; Yuan Gao; Jun Zeng; Min Wei; Handuo Wang; Wenling Zheng; Wenli Ma Journal: Oncol Lett Date: 2015-09-23 Impact factor: 2.967
Authors: Jasper Z Williams; Greg M Allen; Devan Shah; Igal S Sterin; Ki H Kim; Vivian P Garcia; Gavin E Shavey; Wei Yu; Cristina Puig-Saus; Jennifer Tsoi; Antoni Ribas; Kole T Roybal; Wendell A Lim Journal: Science Date: 2020-11-27 Impact factor: 47.728
Authors: Ravid Straussman; Teppei Morikawa; Kevin Shee; Michal Barzily-Rokni; Zhi Rong Qian; Jinyan Du; Ashli Davis; Margaret M Mongare; Joshua Gould; Dennie T Frederick; Zachary A Cooper; Paul B Chapman; David B Solit; Antoni Ribas; Roger S Lo; Keith T Flaherty; Shuji Ogino; Jennifer A Wargo; Todd R Golub Journal: Nature Date: 2012-07-26 Impact factor: 49.962
Authors: Frank Jacobsen; Sharad Nouraie Ashtiani; Pierre Tennstedt; Hans Heinzer; Ronald Simon; Guido Sauter; Hüseyin Sirma; Maria Christina Tsourlakis; Sarah Minner; Thorsten Schlomm; Uwe Michl Journal: Exp Ther Med Date: 2012-10-25 Impact factor: 2.447
Authors: Giuseppe Palmieri; MariaNeve Ombra; Maria Colombino; Milena Casula; MariaCristina Sini; Antonella Manca; Panagiotis Paliogiannis; Paolo Antonio Ascierto; Antonio Cossu Journal: Front Oncol Date: 2015-08-10 Impact factor: 6.244
Authors: Douglas C Marchion; Elona Bicaku; Yin Xiong; Nadim Bou Zgheib; Entidhar Al Sawah; Xiaomang Ba Stickles; Patricia L Judson; Alex S Lopez; Christopher L Cubitt; Jesus Gonzalez-Bosquet; Robert M Wenham; Sachin M Apte; Anders Berglund; Johnathan M Lancaster Journal: Oncol Rep Date: 2013-03-05 Impact factor: 3.906
Authors: Deven Etnyre; Amanda L Stone; Jason T Fong; Ryan J Jacobs; Srijayaprakash B Uppada; Gregory M Botting; Supriya Rajanna; David N Moravec; Manohar R Shambannagari; Zachary Crees; Jennifer Girard; Ceyda Bertram; Neelu Puri Journal: Cancer Biol Ther Date: 2014-06-11 Impact factor: 4.742